TrialBMC neurology2014

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.

Jonathan Calkwood et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.